Abstract
Background: International guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low. Methods: We retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000. Primary endpoint: time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predictive factors by Cox analyses. Results: In total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50-60 Gy (n = 20) or 20-49 Gy (n = 69), stereotactic body RT of 35-50 Gy (SBRT) (n = 36), or brachytherapy of 12-25 Gy (BT) (n = 7). Best objective lesional response was complete (n = 6), partial (n = 52), stable disease (n = 60), progressive disease (n = 14). Median tTTP was 7.6 months (1.0-148.6). In comparison to cRT(20-49Gy), tTTP was significantly longer for cRT(50-60Gy) (multivariate adjusted HR 0.10;95% CI 0.03-0.33;p < 0.001) and SBRT (HR 0.31;95% CI 0.12-0.80;p = 0.016), but not for BT (HR 0.66;95% CI 0.22-1.99;p = 0.46). Toxicity was generally mild and moderate with three grade 3 events. No convincing predictive factors could be established. Conclusions: This largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC.
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| Fakultät: | Medizin |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| ISSN: | 0007-0920 |
| Sprache: | Englisch |
| Dokumenten ID: | 114796 |
| Datum der Veröffentlichung auf Open Access LMU: | 02. Apr. 2024, 08:06 |
| Letzte Änderungen: | 02. Apr. 2024, 08:06 |
- Dokument bearbeiten
